BIOCORP Signs Distribution Agreement for Mallya Technology With Roche Diabetes Care France
30.6.2020 08:30:00 EEST | Business Wire | Press release
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the development and manufacturing of medical devices and smart drug delivery systems, announces today the signature of a distribution contract for its Mallya connected device with Roche Diabetes Care France.
As part of the agreement, Roche Diabetes Care France will distribute Mallya to pharmacies in France. This medical device is an intelligent 2-year reusable injector pen sensor that is compatible with the majority of insulin injection pens, both disposable and reusable. It automatically collects the insulin dose delivered with near 100% accuracy.
In the future, Mallya will also be part of the RocheDiabetes ecosystem consisting of connected blood glucose meters (Accu-Chek Mobile, Accu-Chek Guide) and digital solutions for better patients care.
Gluci-Chek is a smartphone application regularly used by nearly 60,000 diabetic patients in France. It brings together three major functionalities for personalized diabetes management: a carbohydrate calculation tool with visualization of portions on the plate, a self-monitoring glycemic logbook and a graphic visualization of glycemic results.
Thanks to Mallya, the patient will no longer have to manually report the insulin doses injected in the future since, once the sensor is paired with the Gluci-Chek application, the data will be automatically reported and displayed in the blood glucose monitoring logbook, regardless of the insulin pen1.
Frédéric Jacquey, President of Roche Diabetes Care France: “The signature of this agreement with Biocorp represents a fundamental step in the development of our ecosystem to improve the care of diabetic patients and their exchanges with healthcare professionals. With innovative technology like Mallya, we will soon be able to offer a unique offering for optimal patient care that integrates blood glucose data from our meters via Gluci-Chek and automatic insulin data via Mallya.”
Éric Dessertenne, CEO of BIOCORP: “Roche is the second pharmaceutical giant to integrate our Mallya connected device for optimal monitoring of diabetic patients into its commercial offer. I would like to thank the teams at Roche Diabetes Care France for their responsiveness over the last few weeks. This new structuring agreement confirms the ambitions presented to all our shareholders in early 2020 on the market of digitalization of diabetes and the considerable commercial potential of Mallya. With a partner of the calibre of Roche, we are confident that a large number of diabetics will quickly be able to benefit from the real benefits offered by Mallya on the secure monitoring of their daily insulin intake."
ABOUT DE ROCHE DIABETES CARE FRANCE
Roche Diabetes Care is a healthcare company specializing in diabetes. For more than 40 years, it has been designing solutions to meet the needs of both patients and healthcare professionals: medical devices (blood glucose meters, lancing devices, insulin pumps), services (information and therapeutic education support) and digital solutions (applications, platform for sharing blood glucose data between patients and healthcare professionals). By creating an ecosystem connecting medical devices and digital solutions, Roche Diabetes Care is paving the way for personalized diabetes management with the aim of facilitating and optimizing the management and monitoring of this complex disease.
Roche Diabetes Care France is a subsidiary of the Roche Group in France, alongside Roche SAS France and Roche Diagnostics France. For more information, please visit www.roche.fr.
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 54 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com.
Follow us on Twitter @BIOCORPSystems
1 SoloStar de Sanofi – KwikPen de Eli Lilly – FlexPen de Novo Nordisk
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200629005362/en/
Contact information
BIOCORP CONTACTS
Sylvaine Dessard
rp@biocorp.fr
+ 33 (0)6 88 69 72 85
Bruno ARABIAN
barabian@ulysse-communication.com
+33 (0)6 87 88 46 26
ROCHE DIABETES CARE FRANCE CONTACTS
Myriam Hamza
rochediabpresse@havas.com
+33 (0)6 45 87 46 51
Raphaële Badel
Raphaele.badel@roche.com
+33 (0)7 77 34 60 59
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
MOBX to Acquire U.S. Defense Rare Earth, Critical Minerals Company14.5.2026 16:40:00 EEST | Press release
Mobix Labs (Nasdaq: MOBX) today announced a non-binding Letter of Intent to acquire Special Project Delivery LLC ("SPD"), a U.S. company building sovereign supply chains for rare earth elements, critical minerals, and energy storage. The proposed acquisition would extend Mobix Labs' national security work — already supplying U.S. and allied fighter jets, missiles, submarines, and satellites — directly into one of the world's most strategically important industrial sectors. MOBX is moving directly into the supply chain powering modern defense, aerospace, and AI infrastructure. Forward-Looking Statements This press release contains forward-looking statements regarding the proposed acquisition of Special Project Delivery LLC ("SPD"), which are subject to risks and uncertainties described in Mobix Labs' SEC filings and similar provisions under applicable non-U.S. securities laws. The Letter of Intent is non-binding, and there can be no assurance that a definitive agreement will be executed
Flick Raises $6M Seed Round to Redefine How AI Films Are Created14.5.2026 16:19:00 EEST | Press release
Flick (flick.art), an AI-native filmmaking platform founded by award-winning filmmaker Zoey Zhang and founding Instagram engineer Ray Wang, today announced it has raised $6 million in a seed round from True Ventures, GV (Google Ventures), Y Combinator, Lightspeed, Formosa Capital, Pioneer Fund, Olive Tree Capital, and N1 in addition to angel investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514408256/en/ Flick was built around a simple belief: AI should enhance filmmaking, not replace it. Instead of another one-click video generator, Flick gives filmmakers cinematic control through an AI-native creative workflow designed for storytelling, iteration, and artistic direction. Flick will use the seed funding to accelerate product development, expand its core creative tooling for cinematic control, and grow the company’s community of filmmakers. The team is also launching Flick Filmmaker Residency,debuting with 10+ sho
PIF Named as Official Tournament Supporter of FIFA World Cup 2026™14.5.2026 16:08:00 EEST | Press release
PIF and FIFA has announced PIF as an Official Tournament Supporter in North America and Asia of the FIFA World Cup 2026™. The partnership reflects a shared commitment to expanding the growth of football at every level, from the grassroots to elite competition, as well as enabling greater participation in sport by unlocking new opportunities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514974404/en/ 14 May, 2026: Front row (L-R), Romy Gai, Chief Business Officer, FIFA and Kevin Foster, Managing Director and Head of Corporate Affairs, PIF, back row (L-R), H.R.H Prince Faisal Bin Bandar Bin Sultan Al Saud, Vice Chairman, Savvy Games Group, Gianni Infantino, President, FIFA, H.E. Yasir Othman Al-Rumayyan, Governor, PIF and Muhannad AlDawood, Chief Strategy Officer, Qiddiya Investment Company witnessed the signing of the partnership of PIF as Official Tournament Supporter of FIFA World Cup 2026™, incorporating PIF companies
Planet Releases First Light from Latest Pelican Launch, Including Imagery from Sweden’s First Sovereign Satellite14.5.2026 16:04:00 EEST | Press release
Planet Labs PBC (NYSE: PL), a leading provider of daily data and insights about change on Earth, today released first light images from its latest Pelican launch, including the Swedish Armed Forces (SwAF)’s first ever sovereign satellite. Planet launched these three Pelican spacecraft to orbit aboard the CAS500-2 rideshare mission with SpaceX from Vandenberg Space Force Base in California on May 3, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514665846/en/ Ambursu, Nigeria • May 11, 2026 • Altitude: 510 km • Pelican Planet received high-resolution first light imagery from the Pelican satellites within days of their May 3 launch. Each satellite captured imagery from around the world, including Gotland, Sweden, on May 7, 2026, from an altitude of 515 km; Taiyuan, in Shanxi, China, on May 5, 2026, from an altitude of 512 km; and Ambursu, Nigeria, on May 11, 2026, from an altitude of 510 km. As the spacecraft complete
Viz.ai Launches Viz Pulmonary Suite, the First Comprehensive AI-Powered Solution Dedicated to Pulmonary Care Delivery14.5.2026 16:00:00 EEST | Press release
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced the launch of the Viz Pulmonary™ Suite, an integrated AI-powered solution in the Viz.ai enterprise platform, designed to help health systems streamline care delivery for pulmonary conditions. The suite brings acute and chronic pulmonary workflows together in a single solution, giving clinicians a more streamlined way to manage patients to help get them on guideline-directed care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260514994555/en/ With 55%-65% of potential in-network referrals lost due to health system leakage,1 improving continuity across the patient journey becomes a critical challenge. The Viz Pulmonary Suite, which integrates seamlessly with EHR systems, is designed to help pulmonary teams improve retention and outcomes by combining context-aware patient summaries and guideline surfacing with specialized tool
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom